-
HCPLive Under 5 Audio Recap: Week of 03/09
- 2025/03/16
- 再生時間： 4 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 healthcare headlines for March 9-16, 2025:
1. CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial
In the Phase 3 REDEFINE 2 trial, CagriSema showed weight reduction in adults with obesity or overweight and type 2 diabetes, outperforming placebo.
2. Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials
The Phase 3 Launch-HTN and Phase 2 Advance-HTN trials showed lorundrostat effectively reduced blood pressure in uncontrolled or resistant hypertension with a favorable safety profile.
3. PharmaTher Receives New Early June FDA Goal Date for Ketamine
PharmaTher announced the FDA set a new Priority Review goal date of June 4, 2025, for ketamine to treat anesthesia, pain, mental health, and neurological conditions.
4. FDA Awards Fast Track Designation to ATSN-201 Gene Therapy for XLRS
The FDA granted Fast Track designation to ATSN-201 for X-linked retinoschisis, allowing Atsena Therapeutics to seek Priority Review for their gene therapy.
5. FDA Approves First Interchangeable Biosimilar for Omalizumab
The FDA approved omalizumab-igec (OMLYCLO) as the first interchangeable biosimilar to Xolair for asthma, CRSwNP, IgE-mediated food allergy, and CSU.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 healthcare headlines for March 9-16, 2025:
1. CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial
In the Phase 3 REDEFINE 2 trial, CagriSema showed weight reduction in adults with obesity or overweight and type 2 diabetes, outperforming placebo.
2. Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials
The Phase 3 Launch-HTN and Phase 2 Advance-HTN trials showed lorundrostat effectively reduced blood pressure in uncontrolled or resistant hypertension with a favorable safety profile.
3. PharmaTher Receives New Early June FDA Goal Date for Ketamine
PharmaTher announced the FDA set a new Priority Review goal date of June 4, 2025, for ketamine to treat anesthesia, pain, mental health, and neurological conditions.
4. FDA Awards Fast Track Designation to ATSN-201 Gene Therapy for XLRS
The FDA granted Fast Track designation to ATSN-201 for X-linked retinoschisis, allowing Atsena Therapeutics to seek Priority Review for their gene therapy.
5. FDA Approves First Interchangeable Biosimilar for Omalizumab
The FDA approved omalizumab-igec (OMLYCLO) as the first interchangeable biosimilar to Xolair for asthma, CRSwNP, IgE-mediated food allergy, and CSU.